Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 8/20 | 0.85 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.85 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.75 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.74 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.74 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.74 |
| ▸ | CES2 | O00748 | 1/20 | 0.74 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.71 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | SELP | P16109 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555867 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL3817083 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7700077 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL173282 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328013 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL15328011 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL7698286 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL200646 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL17549876 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 | |
| SCHEMBL30555910 | 1.00 | LPAR1 (0.85) | LPAR1ENPP2LPAR3SMN1; SMN2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734964-A1 | LIPID PARTICLES FOR DELIVERING A PAYLOAD | Repertoire Immune Medicines, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | H2MO TECH PTE LTD (SG) | 2026-02-26 | — | — | US | claimed |
| US-12485388-B2 | Composite membrane and method of making the same | H2MO TECHNOLOGY PTE LTD (SG) | 2025-12-02 | — | — | US | claimed |
| CN-119993254-A | Method for structural modification and optimization of PC-PYY peptide based on molecular dynamics simulation and product thereof | 重庆医科大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119522284-A | Lipid Nanoparticle (LNP) based ocular delivery | 克里斯珀医疗股份公司 | 2025-02-25 | — | — | CN | claimed |
| WO-2025007024-A1 | LIPID PARTICLES FOR DELIVERING A PAYLOAD | Repertoire Immune Medicines, Inc. (US) | 2025-01-02 | — | — | WO | claimed |
| CN-115469101-B | Method for enhancing the ability of alpha-synuclein aggregates to disrupt cell membranes | 桂林医学院附属医院 | 2024-12-13 | — | — | CN | claimed |
| CN-118845708-A | Preparation method and application of multifunctional bionic delivery platform capable of efficiently crossing mucosa disorder and inducing mucosa immunity enhancement | 大连理工大学 | 2024-10-29 | — | — | CN | claimed |
| CN-117940118-A | Novel lipid nanoparticles for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117940158-A | Novel lipid nanoparticles comprising phosphatidylserine for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | claimed |
| US-20160120807-A1 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-05 | — | — | US | claimed |
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2013-10-24 | — | — | US | claimed |
| WO-2012052539-A1 | NOVEL NEUTRAL (BIO)MATERIAL | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-04-26 | — | — | WO | claimed |
| EP-2444464-A1 | Novel neutral (bio)material | Centre National de la Recherche Scientifique (CNRS) (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20090202621-A1 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2009-08-13 | — | — | US | claimed |
| EP-1877038-A2 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| WO-2006119121-A2 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2006-11-09 | — | — | WO | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202621-A1 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | LIPG, CD63, SDCBP | LPAR1 59/4885ENPP2 185/4885LPAR3 105/4885 |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | AQP1, AQP4, AQP3 | LPAR1 248/4885ENPP2 2523/4885LPAR3 419/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | LPAR1 217/4885ENPP2 38/4885LPAR3 297/4885 |
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | MAG, FABP7, PMP22 | LPAR1 22/4885ENPP2 220/4885LPAR3 42/4885 |
| US-20160120807-A1 | CELL-SURFACE DECORATION WITH ACTIVE AGENTS | LIPG, CD63, SDCBP | LPAR1 59/4885ENPP2 185/4885LPAR3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.